Genentech Modified CHO Cells for Therapeutic Protein Production
Summary
USPTO published patent application US20260098254A1 by Genentech, Inc. covering modified CHO cells for therapeutic protein production. The application claims methods, cells, and compositions where mammalian cells have reduced or eliminated activity of host cell proteins including lipases, esterases, and hydrolases. Application No. 19408114 was filed December 3, 2025.
What changed
USPTO published Genentech's patent application covering modified mammalian cells, specifically Chinese Hamster Ovary (CHO) cells, engineered for improved recombinant protein production. The cells are modified to reduce or eliminate expression of host cell proteins such as lipases, esterases, and hydrolases, which may improve product quality and manufacturing efficiency.
For pharmaceutical manufacturers and biotechnology companies using CHO cell systems, this patent application represents potential prior art for freedom-to-operate analyses. Companies developing cell engineering approaches for biologics production should monitor prosecution of this application to assess competitive landscape and potential licensing needs.
What to do next
- Monitor for patent grant or office action
- Review claims for freedom-to-operate implications
Archived snapshot
Apr 12, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
MODIFIED MAMMALIAN CELLS
Application US20260098254A1 Kind: A1 Apr 09, 2026
Assignee
Genentech, Inc.
Inventors
Michael Wilson LAIRD, Shahram MISAGHI, Amy SHEN, Anthony TOMLINSON, Inn Huam YUK
Abstract
The present disclosure relates to methods, cells, and compositions for producing a product of interest, e.g., a recombinant protein. In particular, the present disclosure provides improved mammalian cells expressing the product of interest, where the cells (e.g., Chinese Hamster Ovary (CHO) cells) have reduced or eliminated activity, e.g., expression, of certain host cell proteins, e.g., enzymes including, but not limited to, certain lipases, esterases, and/or hydrolases.
CPC Classifications
C12N 15/102 C12N 5/0682 C12N 2510/00
Filing Date
2025-12-03
Application No.
19408114
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.